Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda

Abstract:
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the collaboration and license agreement between Arrowhead and Takeda Pharmaceutical Company Limited announced on October 8, 2020, has now closed.

Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda

Pasadena. CA | Posted on November 27th, 2020

Closing of the transaction was contingent on completion of review under antitrust laws, including the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 in the U.S.

####

About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts .

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400


Investors:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578

www.lifesciadvisors.com

Media:
LifeSci Communications, LLC
Josephine Belluardo, Ph.D.
646-751-4361

www.lifescicommunications.com

Copyright © Arrowhead Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Bioengineered nanoparticles show promise for fibrinogen manufacture, says Journal of Pharmaceutical Analysis study: Scientists engineer a nanoparticle polymer that can selectively bind to fibrinogen in human plasma, presenting a pathway for improved drug development January 14th, 2022

Photon recycling – The key to high-efficiency perovskite solar cells January 14th, 2022

NSF funds Rice effort to measure, preserve quantum entanglement: Physicist Guido Pagano wins CAREER Award to develop tools for quantum computing January 14th, 2022

Tuning the bonds of paired quantum particles to create dissipationless flow: A tunable platform made from atomically thin materials may help researchers figure out how to create a robust quantum condensate that can flow without losing energy January 14th, 2022

Nanomedicine

Bioengineered nanoparticles show promise for fibrinogen manufacture, says Journal of Pharmaceutical Analysis study: Scientists engineer a nanoparticle polymer that can selectively bind to fibrinogen in human plasma, presenting a pathway for improved drug development January 14th, 2022

New photonic effect could speed drug development: Twisted semiconductor nanostructures convert red light into the twisted blue light in tiny volumes, which may help develop chiral drugs January 14th, 2022

UT Southwestern develops nanotherapeutic to ward off liver cancer January 14th, 2022

Preserving the goods: A new technique for isolating intact lysosomes from cell cultures: Scientists advance the study of fragile digestive organelles by developing strategy to rapidly extract them from cells using magnetic nanoparticles January 7th, 2022

Announcements

Nanostructures get complex with electron equivalents: Nanoparticles of two different sizes break away from symmetrical designs January 14th, 2022

New photonic effect could speed drug development: Twisted semiconductor nanostructures convert red light into the twisted blue light in tiny volumes, which may help develop chiral drugs January 14th, 2022

UT Southwestern develops nanotherapeutic to ward off liver cancer January 14th, 2022

The free-energy principle explains the brain January 14th, 2022

Patents/IP/Tech Transfer/Licensing

Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021

HORIBA Medical and CEA-Leti Strengthen Their Partnership to Develop Tomorrow’s Diagnostics at the Point of Care July 21st, 2020

A new study published on the cover of Science could bolster the development of batteries, fuel cells, 3D printing technologies and more May 1st, 2020

New green technology from UMass Amherst generates electricity 'out of thin air' Renewable device could help mitigate climate change, power medical devices February 17th, 2020

Nanobiotechnology

Bioengineered nanoparticles show promise for fibrinogen manufacture, says Journal of Pharmaceutical Analysis study: Scientists engineer a nanoparticle polymer that can selectively bind to fibrinogen in human plasma, presenting a pathway for improved drug development January 14th, 2022

New photonic effect could speed drug development: Twisted semiconductor nanostructures convert red light into the twisted blue light in tiny volumes, which may help develop chiral drugs January 14th, 2022

UT Southwestern develops nanotherapeutic to ward off liver cancer January 14th, 2022

Preserving the goods: A new technique for isolating intact lysosomes from cell cultures: Scientists advance the study of fragile digestive organelles by developing strategy to rapidly extract them from cells using magnetic nanoparticles January 7th, 2022

New-Contracts/Sales/Customers

Bruker Light-Sheet Microscopes at Major Comprehensive Cancer Center: New Advanced Imaging Center Powered by Two MuVi and LCS SPIM Microscopes March 25th, 2021

Veeco Announces Aledia Order of 300mm MOCVD Equipment for microLED Displays: Propel™ Platform First 300mm System with EFEM Designed for Advanced Display Applications October 20th, 2020

GREENWAVES TECHNOLOGIES Announces Next Generation GAP9 Hearables Platform Using GLOBALFOUNDRIES 22FDX Solution October 16th, 2020

Bruker Launches Advanced In-Situ Nanomechanical Test Instrument for Analyzing Materials Deformation in Electron Microscopes: Hysitron PI 89 SEM PicoIndenter Offers Unprecedented Range and Flexibility October 15th, 2020

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project